US 12,234,205 B1
Sulfonylhydrazide derivatives as anticancer agents
Fatmah Ali S. Alasmary, Riyadh (SA); Moustafa E. El-Araby, Riyadh (SA); Linah Saad N. Alqahtani, Riyadh (SA); and Amr M. El-Araby, Riyadh (SA)
Assigned to KING SAUD UNIVERSITY, Riyadh (SA)
Filed by KING SAUD UNIVERSITY, Riyadh (SA)
Filed on May 22, 2024, as Appl. No. 18/671,935.
Int. Cl. C07C 317/48 (2006.01); A61K 31/18 (2006.01); A61K 31/381 (2006.01); A61K 31/4406 (2006.01); A61P 31/00 (2006.01); C07D 213/78 (2006.01); C07D 333/34 (2006.01)
CPC C07C 317/48 (2013.01) [A61K 31/18 (2013.01); A61K 31/381 (2013.01); A61K 31/4406 (2013.01); A61P 31/00 (2018.01); C07D 213/78 (2013.01); C07D 333/34 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A compound having the formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof, wherein:
R is a direct bond, —CH2, or —CH2(Br);
Ar is an optionally substituted phenyl, pyridine, naphthalene, or thiophene being optionally substituted with one or more substituents selected from the group consisting of hydrogen, bromine, COCH3, NO2, CF3, OCH3, methyl, isopropyl, and a second optionally substituted phenyl;
wherein the second optionally substituted phenyl is substituted with a hydrogen, methyl, or methoxy.